247 related articles for article (PubMed ID: 17893567)
21. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial.
Berntsen A; Trepiakas R; Wenandy L; Geertsen PF; thor Straten P; Andersen MH; Pedersen AE; Claesson MH; Lorentzen T; Johansen JS; Svane IM
J Immunother; 2008 Oct; 31(8):771-80. PubMed ID: 18779742
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
[TBL] [Abstract][Full Text] [Related]
24. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
Simons JW; Jaffee EM; Weber CE; Levitsky HI; Nelson WG; Carducci MA; Lazenby AJ; Cohen LK; Finn CC; Clift SM; Hauda KM; Beck LA; Leiferman KM; Owens AH; Piantadosi S; Dranoff G; Mulligan RC; Pardoll DM; Marshall FF
Cancer Res; 1997 Apr; 57(8):1537-46. PubMed ID: 9108457
[TBL] [Abstract][Full Text] [Related]
25. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L
J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666
[TBL] [Abstract][Full Text] [Related]
26. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the response of dendritic cells and regulatory T cells to tumor antigens in patients with renal cell carcinoma.
Hou MM; Chang JW; Pang ST; Chiang YJ; Shen YC; Liao SK; Hsieh JJ; Yeh KY; Chang NJ; Chuang CK
Chang Gung Med J; 2010; 33(1):25-35. PubMed ID: 20184792
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
[TBL] [Abstract][Full Text] [Related]
29. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
30. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.
Hinkel A; Tso CL; Gitlitz BJ; Neagos N; Schmid I; Paik SH; deKernion J; Figlin R; Belldegrun A
J Immunother; 2000 Jan; 23(1):83-93. PubMed ID: 10687141
[TBL] [Abstract][Full Text] [Related]
32. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
Rosenblatt J; Vasir B; Uhl L; Blotta S; Macnamara C; Somaiya P; Wu Z; Joyce R; Levine JD; Dombagoda D; Yuan YE; Francoeur K; Fitzgerald D; Richardson P; Weller E; Anderson K; Kufe D; Munshi N; Avigan D
Blood; 2011 Jan; 117(2):393-402. PubMed ID: 21030562
[TBL] [Abstract][Full Text] [Related]
34. [Antitumor response induced by vaccine of autologous dendritic/tumor fusion cells against renal cell].
Zhou J; Xia JC; Wang H; Wang QJ; Huang LX; Li YQ; Chen SP; Zhou FJ
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):411-4. PubMed ID: 17974271
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
[TBL] [Abstract][Full Text] [Related]
36. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
[TBL] [Abstract][Full Text] [Related]
37. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
Su Z; Dannull J; Heiser A; Yancey D; Pruitt S; Madden J; Coleman D; Niedzwiecki D; Gilboa E; Vieweg J
Cancer Res; 2003 May; 63(9):2127-33. PubMed ID: 12727829
[TBL] [Abstract][Full Text] [Related]
38. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma.
Zhao X; Zhang Z; Li H; Huang J; Yang S; Xie T; Huang L; Yue D; Xu L; Wang L; Zhang W; Zhang Y
Cancer Lett; 2015 Jul; 362(2):192-8. PubMed ID: 25843292
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
Palmer DH; Midgley RS; Mirza N; Torr EE; Ahmed F; Steele JC; Steven NM; Kerr DJ; Young LS; Adams DH
Hepatology; 2009 Jan; 49(1):124-32. PubMed ID: 18980227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
